Forte Biosciences, Inc. (FBRX) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

The price chart for Forte Biosciences, Inc. (FBRX) demonstrates an EV/EBITDA of 0.00. High R&D costs and strict FDA oversight create significant barriers to entry for new players. Stable demand for dermatological pathology therapies guarantees the company long-term revenue. Meanwhile, geopolitical tensions and sanction risks could disrupt raw material logistics and complicate international patent protection.

Forte Biosciences, Inc - FBRX Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 09/06/2026)

Financial and market metric breakdowns for Forte Biosciences Inc. (FBRX)

- market price and analyst price targets:

Price Chart fortebiorx.com|FBRX - Analyst Median Target

- market capitalization details:

Market Value Forte Biosciences|FBRX - Enterprise Value

- book value of equity indicators:

Book Value per Share Forte Biosciences|FBRX - Book Valuation of Business|Market Value to Book Value Ratio fortebiorx.com|FBRX - Total Business Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

FBRX - Company Net Income|Future Profit Forte Biosciences, Inc.|FBRX - Company Value to Net Income|Forward P/E Multiple Forte Biosciences|FBRX - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Forte Biosciences, Inc|FBRX - Operating income before deduction of amortization|Earnings per share for the last twelve months Forte Biosciences|FBRX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months fortebiorx.com|FBRX - Expected net earnings per share growth this year|Earnings growth forecast for next year Forte Biosciences, Inc.

- sales volume and revenue indicators:

FBRX - Company Sales|Projected Sales Volume fortebiorx.com|FBRX - Price-to-Revenue Coefficient|Forward P/S Multiple Forte Biosciences Inc

Initial company analysis:FBRX (Forte Biosciences, Inc.)

The EV/EBITDA multiple determines the value of a business relative to its operating profit before depreciation, taxes, and interest. This metric provides a real-time assessment of changes in the market valuation of debt load during external shocks. By analyzing the EV/EBITDA enterprise value chart, an investor can identify hidden default risks masked by the apparent cheapness of an asset. For Forte Biosciences, Inc. (FBRX), this indicator reflects the financing efficiency of dermatological research and the cost of developing innovative drugs.

Key competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization krystalbio.com KRYS|Total Company Value to Operating Income Before Depreciation Ratio apogeetherapeutics.com (APGE)|ARQT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VCEL - EV/EBITDA Multiple|ORKA: EV/EBITDA Multiple|SMTI - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DBV Technologies|Enterprise Value to Operating Income Before Depreciation SLSN (solesence.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Journey Medical (DERM)|EMPG - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization sol-gel.com SLGL|AXIL: Enterprise Value to Operating Income Before Depreciation|Medicus Pharma - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VRCA (Verrica Pharmaceuticals Inc.)|HOTH: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio BFRI (Biofrontera Inc)|Enterprise Value to EBITDA Ratio VYNE|Enterprise Value to EBITDA Ratio Sonoma Pharmaceuticals (SNOA)|Enterprise Value to EBITDA Ratio QNRX (Quoin Pharmaceuticals Ltd)|EV/EBITDA Multiple Azitra (AZTR)|EV/EBITDA Multiple DRMA (dermatarx.com)|Business Value to Operating Income Before Depreciation ELAB|RVNC: Enterprise Value to EBITDA Ratio